HerpV / Agenus - LARVOL DELTA

Toward the Eradication of Herpes Simplex Virus: Vaccination and Beyond. (PubMed, Viruses) - "Notably, several vaccines-SL-V20, HF10, VC2, and mRNA-1608-have shown promising preclinical results, suggesting that an effective HSV vaccine may be within reach. However, GEN-003 and HerpV have not advanced further despite promising results. Continued progress with these candidates brings us closer to a significant breakthrough in preventing and treating HSV infections."

Journal • Review • Herpes Simplex • Infectious Disease

Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Participants With Recurrent Genital Herpes (clinicaltrials.gov) - P2a; N=80; Completed; Sponsor: Agenus Inc.; Phase classification: P2 ➔ P2a

Clinical • Combination therapy • Phase classification • Herpes Simplex • Infectious Disease • PCR